SurvivorNet Announces New Bladder Cancer Resource Section
/PRNewswire/ -- SurvivorNet, the leading digital health platform, today launched a major expansion of its cancer resource information with the addition of an...
Stay updated with breaking news from Arjun Balar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- SurvivorNet, the leading digital health platform, today launched a major expansion of its cancer resource information with the addition of an...
/PRNewswire/ -- SurvivorNet, the leading digital health platform, today launched a major expansion of its cancer resource information with the addition of an...
email article Adding a targeted agent to chemotherapy failed to improve survival as initial therapy for metastatic urothelial carcinoma, a randomized trial showed. Median overall survival (OS) was about 14 months with cisplatin-containing chemotherapy when paired with either placebo or the angiogenesis inhibitor bevacizumab (Avastin). Progression-free survival (PFS), a secondary endpoint, favored the bevacizumab arm (8.0 vs 6.7 months). Grade ≥3 adverse events (AEs) occurred in a similar proportion of patients in each arm, although bevacizumab-related toxicities occurred more often wi...